EXECUTIVE INTERVIEWS

• Why Takeda Is Focusing So Much On Plasma-Derived Therapies

  Tasked with driving future growth of Takeda’s plasma-derived therapies, Giles Platford, business unit president, shares his approach to partnering, promoting market access, and improving patient experiences.

• With Fundraising, A Track Record Matters: GeoVax’s David Dodd

  Industry veteran David Dodd, chairman and CEO at GeoVax, answers questions about the fundraising environment for small biotechs, and the dangers of toxic warrants.

• Verve Therapeutics: How To Build A Gene Editing Biotech

  Verve Therapeutics’ co-founder and CEO Sekar Kathiresan offers insight into how he launched a gene editing drug company and dosed the first patient in less than four years.

• Executive Outlook: Crafting New Solutions For Persisting Problems

  Creativity will be in high demand, not just to control costs during tough economic conditions, but in key functional areas like business development and external collaboration, ESG (environmental, social, and governance), and diversity, equity and inclusion (DE&I).

• A More Balanced And Stable Future With CDMOs

  Two Industry Experts talk about where they see the outsourcing industry going in the near future.

• Will The Finance And Funding Pendulum Swing Back To Black In 2023?

  Our experts talk about everything from alternative financing arrangements to investment trends that biopharma execs should keep their eyes on.

• Biopharma Public Opinion, Pricing, Politics

  Biopharma sustainability will require the industry not shy from public opinion, but meet it head on. To win short-term battles, however impressively as with creation of the COVID vaccines, may not be enough to secure total victory.

• The Rise Of Computational Biology In Biopharma

  I thought I’d peel a layer off the onion to reveal a trend that’s gaining momentum and having a positive impact during a somewhat negative biopharma news cycle: computational biology.

• How Are DCTs Impacting Your Clinical Sites?

  Where do your sites stand on DCTs? For this article, we spoke with three site experts who discussed the pain points of DCTs, including costs, budgeting, training, support, staffing, resources, and more.

• Building New Solutions For 2023 In Manufacturing And Supply Chain

  In this Q&A, 10 executives provide their thoughts on what the future holds for biopharmaceutical manufacturing and supply chain operations, and which issues will have the most impact.

• How To Reduce COGS & Expedite Commercial-Scale CGT Manufacturing

  Industry luminaries from Kite Pharma, Novartis Gene Therapies, and SwanBio share their knowledge on why the road to cost-efficient and timely commercial manufacturing for cell and gene therapies (CGTs) is paved with AI, automation, clinical trial design, AAV vector efficiencies, skilled team members, and more.

• Managing Through Mixed Trial Results And An Economic Downturn

  From mixed topline results from a Phase 3 trial of lead candidate to the potential need to fund and conduct another trial prior to seeking regulatory approval, Cary Claiborne has been faced with multiple challenges since becoming CEO of Adial Pharma in August.

• Imagine Pharma’s Multilayered Path To Market

  From the looks of its modest open floor plan lab in Pittsburgh’s uptown, it might not be obvious to the casual observer that Imagine Pharma and its nine-person full-time workforce are developing multiple pharmaceutical products across three distinct platforms.

• The Discovering CEO

  In the current world of biopharma companies, the discovery function covers much more than hammering out new drug entities.